Market Cap | 343.04M | P/E | - | EPS this Y | 74.50% | Ern Qtrly Grth | - |
Income | -190.42M | Forward P/E | -1.34 | EPS next Y | 28.60% | 50D Avg Chg | -23.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
Dividend | N/A | Price/Book | 1.40 | EPS next 5Y | - | 52W High Chg | -71.00% |
Recommedations | 3.60 | Quick Ratio | 6.49 | Shares Outstanding | 114.91M | 52W Low Chg | 6.00% |
Insider Own | 48.58% | ROA | -48.45% | Shares Float | 38.22M | Beta | 0.85 |
Inst Own | 42.72% | ROE | -102.85% | Shares Shorted/Prior | 6.40M/6.27M | Price | 3.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 654,935 | Target Price | 1.00 |
Oper. Margin | - | Earnings Date | May 3 | Volume | 409,993 | Change | -5.63% |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
B of A Securities | Underperform | Dec 26, 23 |
Leerink Partners | Market Perform | Dec 22, 23 |
Piper Sandler | Neutral | Dec 22, 23 |
JP Morgan | Underweight | Dec 22, 23 |
B of A Securities | Buy | Aug 18, 23 |
Morgan Stanley | Overweight | Aug 7, 23 |
SVB Securities | Outperform | Apr 26, 23 |
Morgan Stanley | Overweight | Jan 27, 23 |
SVB Leerink | Outperform | Jan 23, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Dec 27 | Sell | 0.7354 | 28,335 | 20,838 | 97,500 | 01/02/24 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Oct 19 | Sell | 1.56 | 715 | 1,115 | 126,238 | 10/23/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Oct 19 | Sell | 1.58 | 8,581 | 13,558 | 881,977 | 10/23/23 |
Sinha Vikas | See Remarks See Remarks | Oct 19 | Sell | 1.56 | 2,707 | 4,223 | 1,170,239 | 10/23/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Oct 03 | Sell | 1.9763 | 1,325 | 2,619 | 890,558 | 10/05/23 |
Sinha Vikas | See Remarks See Remarks | Oct 03 | Sell | 1.9763 | 755 | 1,492 | 1,172,946 | 10/05/23 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Oct 03 | Sell | 1.9763 | 222 | 439 | 126,953 | 10/05/23 |
Sinha Vikas | See Remarks See Remarks | Aug 17 | Sell | 2.4955 | 10,516 | 26,243 | 1,173,701 | 08/21/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Aug 17 | Sell | 2.64 | 15,416 | 40,698 | 891,883 | 08/21/23 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Aug 17 | Sell | 2.4955 | 1,653 | 4,125 | 127,175 | 08/21/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Jul 19 | Sell | 3.5615 | 8,342 | 29,710 | 907,299 | 07/21/23 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Jul 19 | Sell | 3.45 | 684 | 2,360 | 128,828 | 07/21/23 |
Sinha Vikas | See Remarks See Remarks | Jul 19 | Sell | 3.45 | 2,635 | 9,091 | 1,184,217 | 07/21/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Jul 05 | Sell | 3.0451 | 5,275 | 16,063 | 915,641 | 07/06/23 |
Sinha Vikas | See Remarks See Remarks | Jul 05 | Sell | 3.0451 | 2,983 | 9,084 | 1,186,852 | 07/06/23 |
GILEAD SCIENCES, INC. | 10% Owner 10% Owner | Jun 27 | Buy | 3.75 | 2,930,870 | 10,990,762 | 16,635,286 | 06/28/23 |
Sinha Vikas | See Remarks See Remarks | Apr 19 | Sell | 3.67 | 2,683 | 9,847 | 1,185,055 | 04/21/23 |
Sinha Vikas | See Remarks See Remarks | Jan 19 | Sell | 5.11 | 6,537 | 33,404 | 1,030,238 | 01/23/23 |
Miller Edward | General Counsel General Counsel | Jan 19 | Sell | 5.11 | 2,573 | 13,148 | 148,458 | 01/23/23 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Jan 19 | Sell | 5.11 | 1,895 | 9,683 | 74,004 | 01/23/23 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Jan 19 | Sell | 5.0777 | 34,435 | 174,851 | 601,607 | 01/23/23 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Nov 10 | Sell | 8.09 | 24,000 | 194,160 | 75,899 | 11/14/22 |
Sinha Vikas | See Remarks See Remarks | Oct 19 | Sell | 9.3607 | 1,449 | 13,564 | 1,036,775 | 10/24/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Oct 19 | Sell | 9.3607 | 1,070 | 10,016 | 399,800 | 10/24/22 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Oct 19 | Sell | 8.65 | 13,679 | 118,323 | 99,899 | 10/24/22 |
Miller Edward | General Counsel General Counsel | Oct 19 | Sell | 9.3607 | 553 | 5,176 | 249,377 | 10/24/22 |
Atillasoy Ercem | See Remarks See Remarks | Oct 19 | Sell | 8.92 | 2,095 | 18,687 | 131,372 | 10/24/22 |
Hallal David | Director Director | Oct 19 | Sell | 8.45 | 600,000 | 5,070,000 | 138,153 | 10/21/22 |
Hallal David | Director Director | Sep 29 | Sell | 7.3523 | 400,000 | 2,940,920 | 720,965 | 09/30/22 |
Brainard Diana | Chief Executive Offi.. Chief Executive Officer | Aug 18 | Sell | 7.7626 | 4,564 | 35,429 | 637,548 | 08/19/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Aug 16 | Sell | 8.3 | 15,590 | 129,397 | 386,363 | 08/17/22 |
Hallal David | Director Director | Jul 21 | Sell | 5.3295 | 4,227 | 22,528 | 2,073,662 | 07/21/22 |
Sinha Vikas | See Remarks See Remarks | Jul 20 | Sell | 5.2145 | 1,432 | 7,467 | 938,224 | 07/21/22 |
Atillasoy Ercem | See Remarks See Remarks | Jul 20 | Sell | 5.2145 | 563 | 2,936 | 135,000 | 07/21/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Jul 20 | Sell | 5.2145 | 1,058 | 5,517 | 401,953 | 07/21/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Jun 03 | Sell | 3.63 | 515 | 1,869 | 389,011 | 07/06/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | May 17 | Sell | 4.4009 | 15,262 | 67,167 | 389,526 | 05/18/22 |
Bornstein Jeffrey S | Director Director | Apr 26 | Buy | 4.6393 | 5,000 | 23,197 | 40,197 | 04/28/22 |
Hallal David | Director Director | Apr 21 | Sell | 5.87 | 4,227 | 24,812 | 2,143,614 | 04/22/22 |
Sinha Vikas | See Remarks See Remarks | Apr 20 | Sell | 6.6843 | 1,162 | 7,767 | 906,633 | 04/22/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Apr 20 | Sell | 6.6843 | 852 | 5,695 | 404,788 | 04/22/22 |
Atillasoy Ercem | See Remarks See Remarks | Apr 20 | Sell | 6.27 | 2,040 | 12,791 | 121,563 | 04/22/22 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Apr 20 | Sell | 6.6843 | 276 | 1,845 | 80,368 | 04/22/22 |
Hallal David | Director Director | Mar 10 | Sell | 7.46 | 65,725 | 490,308 | 2,147,841 | 03/11/22 |
Bornstein Jeffrey S | Director Director | Feb 10 | Buy | 8.87 | 5,000 | 44,350 | 35,197 | 02/10/22 |
Hallal David | Director Director | Jan 24 | Sell | 8.0052 | 17,100 | 136,889 | 2,213,566 | 01/25/22 |
VAN BEEK JEROEN B | Chief Commercial Off.. Chief Commercial Officer | Jan 20 | Sell | 8.7526 | 4,656 | 40,752 | 398,222 | 01/24/22 |
Hagen Brett R | Chief Accounting Off.. Chief Accounting Officer | Jan 20 | Sell | 8.7526 | 1,563 | 13,680 | 63,202 | 01/24/22 |
Sinha Vikas | See Remarks See Remarks | Jan 20 | Sell | 8.7526 | 6,450 | 56,454 | 858,957 | 01/24/22 |
Leen Ann M. | Chief Scientific Off.. Chief Scientific Officer | Nov 12 | Sell | 22.28 | 20,988 | 467,613 | 2,288,154 | 11/16/21 |